title: Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.
abstract: Betaglycan is a type III TGFbeta receptor that modulates cellular sensitivity to inhibins and TGFbeta. Previous studies have suggested that betaglycan acts as a tumor suppressor in certain human epithelial cancers. However, the roles of betaglycan in ovarian granulosa cell tumors (GCTs) are poorly understood. The objective of this study was to determine whether human GCTs exhibit betaglycan expression and, if so, what impact this receptor has on tumor biology. Real-time PCR was used to quantify betaglycan transcripts in human GCTs (n = 17) and normal premenopausal ovaries (n = 11). This analysis established that GCTs exhibited a significant 2-fold lower mean betaglycan mRNA level as compared with the normal ovary (P < 0.05). Similarly, two human GCT cell lines, KGN and COV434, exhibited low betaglycan expression and poor responsiveness to TGFbeta and inhibin A in luciferase reporter assays, which was restored by stable transfection of wild-type betaglycan. Betaglycan significantly increased the adhesion of COV434 (P < 0.05) and KGN (P < 0.0001) cells, decreased cellular invasion through Matrigel, and inhibited wound healing. Expression of mutant forms of betaglycan that are defective in TGFbeta and/or inhibin binding in each GCT cell line revealed that the inhibitory effects of betaglycan on wound healing were most strongly linked to the inhibin-binding region of betaglycan. Furthermore, knockdown of INHA mRNA expression abrogated the betaglycan-mediated inhibition of wound healing and invasion, whereas both INHA silencing and TGFbeta neutralization abolished the betaglycan-mediated increase in adhesion to substrate. These data suggest that loss of betaglycan contributes to the pathogenesis of GCTs.
authors.affiliation: Prince Henry's Institute, Clayton, Victoria 3168 Australia. maree.bilandzic@princehenrys.org
authors.forename: Maree
authors.initials: M
authors.lastname: Bilandzic
authors.forename: Simon
authors.initials: S
authors.lastname: Chu
authors.forename: Paul G
authors.initials: PG
authors.lastname: Farnworth
authors.forename: Craig
authors.initials: C
authors.lastname: Harrison
authors.forename: Peter
authors.initials: P
authors.lastname: Nicholls
authors.forename: Yao
authors.initials: Y
authors.lastname: Wang
authors.forename: Ruth M
authors.initials: RM
authors.lastname: Escalona
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Fuller
authors.forename: Jock K
authors.initials: JK
authors.lastname: Findlay
authors.forename: Kaye L
authors.initials: KL
authors.lastname: Stenvers
mesh_terms: D028341:Activins / Q000235:genetics / Q000378:metabolism; D002448:Cell Adhesion / Q000502:physiology; D045744:Cell Line, Tumor; D005260:Female; D020868:Gene Silencing; D006106:Granulosa Cell Tumor / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007265:Inhibins / Q000235:genetics / Q000378:metabolism; D008024:Ligands; D009361:Neoplasm Invasiveness; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D011509:Proteoglycans / Q000235:genetics / Q000378:metabolism*; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism*; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism
chemical_list: D008024:Ligands; D011509:Proteoglycans; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; C094377:inhibin-alpha subunit; D028341:Activins; C071736:betaglycan; D007265:Inhibins